PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 60.73M 5.7M 7.79M | Sales 2025 * | 514M 48.3M 66.02M | Capitalization | 2.31B 216M 296M |
---|---|---|---|---|---|
Net income 2024 * | -289M -27.13M -37.09M | Net income 2025 * | 125M 11.74M 16.04M | EV / Sales 2024 * | 35.2 x |
Net cash position 2024 * | 167M 15.69M 21.44M | Net cash position 2025 * | 226M 21.19M 28.96M | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
-7.68
x | P/E ratio 2025 * |
14.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 21-03-31 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |